Inotiv Inc
NASDAQ:NOTV
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Inotiv Inc
NASDAQ:NOTV
|
US |
|
Somec SpA
MIL:SOM
|
IT |
Inotiv Inc
Inotiv, Inc. operates as a pharmaceutical development company, which engages in the provision of drug discovery, development services, and analytical instruments. The company is headquartered in West Lafayette, Indiana and currently employs 541 full-time employees. The firm focuses on providing drug developers with scientific research and analytical instrumentation. The firm operates through two segments, including Contract Research Services and Research Products. The Contract Research Services segment provides screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance and quality control testing. The Research Products segment offers two principal product lines, including analytical products and in vivo sampling products. Analytical products consist of liquid chromatographic and electrochemical instruments with associated accessories. In vivo sampling products consist of the Culex family of automated in vivo sampling and dosing instruments.
Inotiv, Inc. operates as a pharmaceutical development company, which engages in the provision of drug discovery, development services, and analytical instruments. The company is headquartered in West Lafayette, Indiana and currently employs 541 full-time employees. The firm focuses on providing drug developers with scientific research and analytical instrumentation. The firm operates through two segments, including Contract Research Services and Research Products. The Contract Research Services segment provides screening and pharmacological testing, nonclinical safety testing, formulation development, regulatory compliance and quality control testing. The Research Products segment offers two principal product lines, including analytical products and in vivo sampling products. Analytical products consist of liquid chromatographic and electrochemical instruments with associated accessories. In vivo sampling products consist of the Culex family of automated in vivo sampling and dosing instruments.
DSA Strength: DSA revenue grew 12% year-over-year in Q1, with Discovery revenue up 26% and Safety Assessment up 7%, driving the company's overall growth.
Weak RMS Performance: RMS revenue declined 5.4% due to a 25% drop in NHP volumes, which weighed on overall margins and adjusted EBITDA.
Adjusted EBITDA: Adjusted EBITDA was $1.8 million, down from $2.6 million in the prior year quarter, mainly due to RMS margin pressures and higher costs.
Cost Optimization: The company exited two leased RMS facilities as part of ongoing site optimization, expecting further cost benefits to show up in future quarters.
No Formal Guidance: Management is not providing formal financial guidance for FY 2026, citing market and demand uncertainty, but expressed confidence in improvement as the year progresses.
Positive DSA Awards Trend: DSA net new awards rose 27% in Q1 and 34% on a trailing 12-month basis, with book-to-bill remaining above 1, indicating strong demand momentum.
